Achillion Pharmaceuticals



Lung diseases of all types are increasing in prevalence and are expected to become the third leading cause of illness and death worldwide by 2020. A growing number of studies link complement activation to the exacerbation of lung injury, particularly through its role in inflammation, in a variety of pulmonary conditions, including chronic obstructive pulmonary disease (COPD)1. Achillion is working to select and optimize potential candidates from its small-molecule factor D inhibitor library that are ideal for inhalation delivery and could represent a novel treatment approach for COPD and other respiratory conditions.

1 Panda PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol. 2014 Oct; 51(4): 467–473. dos:  10.1165/rcmb.2013-0485TR